Cara Therapeutics(US:CARA)2025-08-14 20:31Financial Performance - Tvardi Therapeutics reported a net income of $4.2 million for Q2 2025, compared to a net loss of $7.0 million in Q2 2024, primarily due to a $12.8 million remeasurement gain on Convertible Notes[10] - Research and development expenses decreased to $5.8 million in Q2 2025 from $6.5 million in Q2 2024, a reduction of approximately 10.8%[8] - General and administrative expenses increased to $3.1 million in Q2 2025 from $650,000 in Q2 2024, reflecting a rise of approximately 376.9% due to higher professional fees related to the merger[9] Cash and Assets - Cash, cash equivalents, and short-term investments as of June 30, 2025, were $41.0 million, up from $31.6 million as of December 31, 2024[11] - The total assets of Tvardi increased to $43.75 million as of June 30, 2025, compared to $35.20 million as of December 31, 2024[17] - Total liabilities decreased significantly to $10.82 million as of June 30, 2025, from $40.83 million as of December 31, 2024[17] - The company anticipates sufficient cash runway to fund operations into Q4 2026[4] Clinical Development - The company is on track to report topline data from the REVERT IPF Phase 2 clinical trial in Q4 2025[4] - An Investigational New Drug (IND) application for the second clinical candidate, TTI-109, was submitted to the FDA in June 2025[6] Corporate Changes - The merger with Cara Therapeutics has transitioned Tvardi into a publicly traded company[6]